

pLIVE™ *In Vivo* Expression and Reporter Vectors

Product	Component(s)	Quantity	Product No.
pLIVE™ Vector*	pLIVE™ Vector	20 µg	MIR 5420
pLIVE™ Vector/ <i>lacZ</i> Control Vector Kit	pLIVE™ and pLIVE™- <i>lacZ</i> Vectors	20 µg each	MIR 5520
pLIVE™ Vector/SEAP Control Vector Kit	pLIVE™ and pLIVE™-SEAP Vectors	20 µg each	MIR 5620
pLIVE™ Vector Complete System (All 3 Vectors)	pLIVE™, pLIVE™- <i>lacZ</i> , and pLIVE™-SEAP Vectors	20 µg each	MIR 5320

*Patent pending. Please contact Mirus Bio Corporation to order bulk quantities.

1.0 DESCRIPTION

1.1 General Information



As a leader in the development of the hydrodynamic tail vein injection technique for the delivery of nucleic acids to the mouse liver, Mirus Bio Corporation has developed a state of the art liver-specific transgene expression vector, the pLIVE™ (Liver In Vivo Expression) Vector. The pLIVE™ Vector is designed for high level, prolonged expression of transgenes in mouse liver. This vector utilizes a chimeric promoter composed of the minimal mouse albumin promoter and the mouse alpha fetoprotein enhancer II. Two introns have been engineered into the expression plasmid so that they will be present in the primary transcript, in turn increasing expression of the transgene. Downstream of the first intron is a multiple cloning site (MCS) with eight unique restriction sites allowing for simple insertion of the gene of interest. Together this chimeric promoter and the two introns are capable of promoting high level transgene expression in the liver for extended lengths of time compared to classic promoters such as the cytomegalovirus immediate early promoter (CMV).


In addition to the pLIVE™ Vector, two reporter vectors derived from the pLIVE™ Vector, pLIVE™-*lacZ* and pLIVE™-SEAP Vectors, can be used as positive controls for the hydrodynamic tail vein injection procedure or any liver specific delivery methodologies. Expression of the *E. coli lacZ* gene from pLIVE™-*lacZ* Vector can be monitored in the liver using either classical X-gal staining of liver tissue sections or quantitative β-galactosidase assays using liver lysates. Expression of human placental secreted alkaline phosphatase (SEAP) from pLIVE™-SEAP Vector can be easily monitored using a quantitative assay of mouse serum following delivery. The high level, long term liver-specific expression of transgenes from the pLIVE™ Expression Vector, as well as the availability of the positive control pLIVE™-*lacZ* and pLIVE™-SEAP Reporter Vectors, make the pLIVE™ Vector series the ideal choice for *in vivo* liver expression studies in mice.

1.2 Specifications

Concentration:	Each vector DNA is supplied at 1 mg/ml in TE buffer (10 mM Tris, pH 7.5, 0.1 mM EDTA)
Storage:	Store vector DNA at -20°C. Prior to use, thaw vector DNA at room temperature, vortex, and quick spin in a microcentrifuge.
Stability:	1 year from the date of purchase when stored at -20°C

1.3 Vector Maps





1.4 Plasmid Features

FEATURE	VECTOR (bp position)		
	pLIVE™	pLIVE™-lacZ	pLIVE™-SEAP
Vector Size (bp)	3423	6509	4992
Mouse Alpha Fetoprotein Enhancer II	8 – 226	8 – 226	8 – 226
Mouse Minimal Albumin Promoter	269 - 586	269 - 586	269 - 586
Intron 1	602 - 900	602 - 900	602 - 900
MCS (<i>NheI/AscI/SalI/SmaI/BamHI/SacI/SacII/XhoI</i>)*	908 - 961	n/a**	n/a
<i>E. coli lacZ</i> Coding Sequence	n/a	978 - 4034	n/a
Human Placental Secreted Alkaline Phosphatase (SEAP) ORF	n/a	n/a	933 – 2489
Intron 2	988 - 1329	4074 - 4415	2557 - 2898
Polyadenylation Region	1472 - 1805	4558 - 4891	3041 - 3374
Kanamycin Resistance Gene	1888 - 2683	4974 - 5768	3457 - 4251
pUC origin	2746 - 3334	5832 - 6420	4315 - 4903

* MCS (Multiple Cloning Sites) restriction enzyme sites can be used for the insertion of the gene of interest

** not applicable

2.0 GENERAL EXPERIMENTAL PROCEDURES


DISCLAIMER: For research use only. Small-animal research is regulated by federal laws and regulations. Extensive information on this topic is provided by the NIH Office for Protection from Research Risks (<http://www.hhs.gov/ohrp/>). This kit does not confer any approval from regulatory agencies to conduct animal research. Follow all applicable laws and regulations pertaining to the care and use of animals in research. All personnel who handle animals should be properly trained. Familiarity with performing tail vein injections in your particular mouse species will greatly facilitate this procedure.

NOTICE: *In vivo* hydrodynamic delivery of non-viral nucleic acids is covered by patents and patent applications of Mirus Bio Corporation, including U.S. Patent 6,627,616; 6,379,966 and related filings worldwide. Purchase of this product does not provide a license to this delivery technology, which is required for all research and commercial uses by for-profit entities. To inquire about a license, please contact Mirus Bio Corporation.

2.1 Cloning the Gene of Interest (GOI) into the pLIVE™ Vector

Clone the GOI into the MCS (Figure 1.) of the pLIVE™ Vector using standard molecular biology techniques. For detailed information on cloning, see *Current Protocols in Molecular Biology*¹ or *Molecular Cloning: A Laboratory Manual*².

Figure 1. DNA Sequence of the pLIVE™ Vector MCS.



A. Compatible Restriction Enzymes

Many of the overhangs produced by the restriction enzymes in this MCS are compatible with the overhangs produced by other restriction enzymes.

Nhe I is compatible with *Avr* II, *Spe* I, *Sty* I (C/CTAGG), and *Xba* I.

Asc I is compatible with *Afl* III (A/CGCGT) and *Mlu* I.

Sal I is compatible with *Psp*X I and *Xho* I.

Sma I produces a blunt end and can be ligated to any other blunt-ended fragment. *Xma* I also cuts at the *Sma* I recognition sequence and produces a 5' overhang that is compatible with *Age* I, *Bsa*W I, *Bsp*E I, *Bsr*F I, *Ngo*M IV, and *Sgr*A I.

*Bam*H I is compatible with *Bcl* I and *Bgl* II.

Sac II is compatible with *Bsi*E I.

Xho I is compatible with *Sal* I.

B. General Cloning Architecture

When cloning the GOI fragment into the MCS of the pLIVE™ Vector, be certain to include a stop codon at the 3' end of the GOI open reading frame, and design the sequence around the ATG start codon (underlined) such that it matches the Kozak translational consensus sequence: (G/A)NNATGG^{3,4}. This consensus sequence will promote the optimal translation efficiency of the GOI mRNA.

1. Due to the presence of intron 2 downstream of the MCS (Section 1.3), cloning a GOI such that the stop codon is more than 50 bp upstream of the 5' end of intron 2 could induce nonsense mediated decay (NMD) of the GOI mRNA^{5,6} and reduce expression. In order to avoid NMD, clone the GOI open reading frame into the MCS such that the 3' end of the ORF is within 50 bp of the 5' end of intron 2 (bp 988). If the GOI 3' end restriction site is engineered immediately downstream of the GOI stop codon, the fragment can be cloned into the *Sac* I, *Sac* II, or *Xho* I sites and the stop codon will be within 50 bp of the 5' end of intron 2.
2. The 5' end of the GOI ORF can be cloned using any of the restriction sites in the MCS.

C. Confirm Sequence

If the GOI fragment was generated by the polymerase chain reaction (PCR) before cloning into the pLIVE™ Vector, it is important to sequence the entire cloned GOI fragment to verify that no detrimental mutations were introduced during PCR amplification.

2.2 Preparation of Plasmid DNA for Delivery

Once the correct clone has been identified and verified, amplify the vector DNA in a suitable *E. coli* strain such as DH5 α or DH10b using 30 μ g/ml kanamycin sulfate in the culture media for plasmid selection. Use a plasmid purification system that results in vector DNA with endotoxin (lipopolysaccharides, pyrogens) levels that are <30 EU/mg of DNA which are suitable for *in vivo* delivery. If the plasmid DNA is contaminated with endotoxin, the MiraCLEAN™ Endotoxin Removal Kit (MIR 5900 or MIR 5910) can be used to easily remove the unwanted endotoxin. If the pLIVE™-*lacZ* and pLIVE™-SEAP Reporter Vectors are going to be used for animal studies, they will have to be amplified in *E. coli* as well using the same procedure.

2.3 Hydrodynamic Tail Vein Injections

NOTE: The pLIVE™ Vectors can be used in conjunction with any delivery technique that will deliver the vector DNA to the mouse liver efficiently. As a leader in the development of the highly efficient hydrodynamic tail vein injection procedure for the delivery of nucleic acids, Mirus Bio uses and recommends this technique for the delivery of nucleic acids to the liver.

Deliver the pLIVE™ Vector DNA (pLIVE™-GOI, pLIVE™-*lacZ*, or pLIVE™-SEAP) to the mouse liver using the hydrodynamic tail vein injection procedure developed by Mirus Bio (See Related Products Section). Normally, 10-50 μ g of plasmid DNA per mouse is delivered using this technique and the amount injected will ultimately depend on the level of expression necessary for the experiment. The hydrodynamic tail vein injection procedure is explained in detail in the *TransIT*®-QR (MIR 5240) and *TransIT*®-EE (MIR 5340) Hydrodynamic Delivery Solution protocols (ML041 and ML043, respectively). The *TransIT*®-QR Hydrodynamic Delivery Solution (MIR 5240) is optimized for efficient delivery of naked nucleic acids, including the pLIVE™ Vectors, to the liver, with the additional benefit that the injected mice demonstrate quick recovery post-injection compared to animals injected using normal saline as the delivery solution. The *TransIT*®-EE Hydrodynamic Delivery Solution (MIR 5340) is formulated to promote enhanced expression from plasmid expression vectors such as the pLIVE™ Vectors after delivery to the liver using hydrodynamic tail vein injections. The expression level obtained using the *TransIT*®-EE Delivery Solution is approximately 2-3 fold greater than the level of expression obtained after delivery of DNA using the *TransIT*®-QR Delivery Solution.

NOTE: For additional information about hydrodynamic tail vein injections, call the Mirus Bio technical support team at 1.888.530.0801 or email techsupport@mirusbio.com. An online instructional video of the hydrodynamic tail vein injection procedure is also available. Please contact Mirus Bio technical support for access to the online video.

2.4 Detection of Gene Expression After Delivery

NOTE: Optimal transgene expression from the pLIVE™ Vectors generally occurs 3-5 days post-delivery.

Detection of *lacZ* Gene Expression from the pLIVE™-*lacZ* Vector in the Liver

Liver *lacZ* expression from the pLIVE™-*lacZ* Vector can be detected using two different methods. Liver tissue sections can be stained with X-gal, turning the β -galactosidase positive (*lacZ* expressing) cells blue. This assay is useful when a measure of vector delivery efficiency is important or a visual readout of delivery is desired.

Mirus Bio's Beta-galactosidase Staining Kit (MIR 2600) has been developed for this type of cell staining and is recommended for this application. For additional details see the Beta-Gal Staining Kit protocol.

LacZ expression can also be quantified in liver lysates using a chemiluminescent assay, such as the Galacto-Light™ Kit (Applied Biosystems). As a general recommendation, livers should be harvested and lysed in approximately 4 ml of lysis buffer. The liver lysates should then be diluted 100-500 fold before being assayed to ensure accurate quantification.

Detection of SEAP Gene Expression from the pLIVE™-SEAP Vector in the Liver

SEAP expression from the pLIVE™-SEAP Vector can be detected in the serum of mice using a quantitative chemiluminescent assay, such as the Phospha-Light™ Kit (Applied Biosystems). Serum samples may require approximately 80-300 fold dilution depending on the amount of vector DNA delivered and the expression level of SEAP obtained.

3.0 TROUBLESHOOTING

Poor Expression of the Gene of Interest (GOI)

- **Poor delivery of the pLIVE™ Vector**

Poor delivery will result in low levels of expression from a pLIVE™ Vector. If using the hydrodynamic tail vein injection, be certain to inject the full volume of the nucleic acids solution rapidly (4-7 seconds) with steady pressure into the tail vein. For more details on hydrodynamic delivery, consult the *TransIT*®-QR Hydrodynamic Delivery Solution protocol (ML041) or contact Mirus Bio technical support at 1.888.530.0801 or techsupport@mirusbio.com. Use the pLIVE™-*lacZ* or pLIVE™-SEAP Reporter Vectors to verify that the delivery technique, including the hydrodynamic tail vein injection is performed efficiently.

- **Poor translational context surrounding the ATG start codon of the GOI**

The best translation efficiency in mammalian cells is usually obtained when the sequence surrounding the ATG start codon of the gene of interest has the following sequence: (G/A)NNATGG^{3,4}.

- **Suboptimal location of the GOI stop codon in the pLIVE™ Vector MCS**

If the stop codon of the GOI open reading frame is more than 50 bp upstream of the 5' end of intron 2 (bp 988), nonsense mediated decay could be induced in the cell, leading to a decreased level of the GOI mRNA in the cell^{5,6}. We have seen a 2-3 fold decrease in the level of luciferase expression when the luciferase stop codon is more than 50 bp upstream of the start of intron 2.

- **Suboptimal amount of pLIVE™ Vector DNA delivered**

Increase the amount of vector DNA delivered. Using the pLIVE™-*lacZ* or pLIVE™-SEAP Vectors, scientists at Mirus Bio routinely deliver 10 µg of vector DNA per mouse and observe robust expression of the reporter genes using the hydrodynamic tail vein injection procedure.

- **The protein product expressed from the delivered transgene induces an immune response in the mouse**

If the transgene protein product is immunogenic in mice, it will induce an immune response which will ultimately lead to the clearance of the liver cells expressing the transgene. An immune response in the mice will usually be indicated by a rapid decrease in the level of expression from the delivered pLIVE™ Vector 10-14 days post-delivery. Harvest the mouse livers at earlier timepoints post-injection and reassay for expression. Alternatively, use C57Bl/6 mice which tend to be less immuno-responsive to closely related human genes.

Difficulty Working with the pLIVE™ Vectors

- **No transformants obtained with a pLIVE™ Vector**

The various pLIVE™ Vectors contain a kanamycin selectable marker. Be certain to propagate the *E. coli* cells harboring the pLIVE™ Vectors in liquid and solid media containing 30 µg/ml kanamycin sulfate to select for maintenance of the vector. DO NOT USE ampicillin.

- **Poor plasmid yields from plasmid preparations**

The vector backbone of the pLIVE™ Vectors is derived from pUC, a high copy number plasmid. When purifying plasmid DNA using Qiagen's Maxiprep Kit or Marligen's High Purity Plasmid Maxiprep Kit (MIR 11452-018), use 100 ml of an LB + 30 µg/ml kanamycin liquid culture. Using the Marligen High Purity Plasmid Maxiprep kit, a yield of 750 µg of pLIVE™ Vector DNA is routinely obtained from 100 ml's of bacterial culture.

For specific questions or concerns, please contact Mirus Bio's Technical Support at 888.530.0801 or techsupport@mirusbio.com.

For a list of citations using Mirus Bio's products, please visit the Technical Resources section of our website. (www.mirusbio.com)

4.0 REFERENCES

1. Ausubel, F.M. *et al.* (2005) *Current Protocols in Molecular Biology* John Wiley & Sons, Inc. Hoboken, New Jersey.
2. Sambrook, J. *et al.* (1989) *Molecular Cloning: A Laboratory Manual*. Cold Spring Harbor Press, New York.
3. Kozak, M. (1987) *Nuc. Acids Res.* 15:8125-8148.
4. Kozak, M. (1991) *J. Cell Biol.* 115:887-903.
5. Beyers, P.H. (2002) *J. Clin. Invest.* 109:3-6.
6. Baker, K.E. and R. Parker (2004) *Curr. Opin. Cell Biol.* 16:293-299.

5.0 RELATED PRODUCTS

For detecting β -galactosidase expression in liver sections:

Beta-Gal Staining Kit (Product # MIR 2600)

Plasmid DNA Purification Kits:

High Purity Plasmid Purification Systems (Product # MIR 11452-018, 11452-026, 11451-010, 11451-028, 11449-014, and 11449-022)

Endotoxin removal from vector DNA preparations:

MiraCLEAN[®] Endotoxin Removal Kit (Product # MIR 5900 and MIR 5910)

In Vivo Gene Delivery Kits:

TransIT[®]-In Vivo Gene Delivery System (Product # MIR 5100 and MIR 5125)

TransIT[®]-QR Hydrodynamic Delivery Solution (Product # MIR 5240)

TransIT[®]-QR Hydrodynamic Delivery Starter Kit (Product # MIR 5210)

TransIT[®]-EE Hydrodynamic Delivery Solution (Product # MIR 5340)

TransIT[®]-EE Hydrodynamic Delivery Starter Kit (Product # MIR 5310)

The performance of this product is guaranteed for 1 year from the date of purchase if stored and handled properly.

Mirus Bio Reagents are covered by United States Patent No. 5,744,335; 5,965,434; 6,180,784; 6,383,811; 6,593,465 and patents pending.

The pLIVE[™] Vectors are covered by patents pending of Mirus Bio Corporation. Purchase of this product conveys a license for use of this product only for research by the purchaser in not-for-profit institutions. The purchaser may only transfer vectors modified with sequences for protein expression to researchers in not-for-profit institutions who agree to be bound by this license. This license does not include the right to perform research at or on behalf of a for-profit entity, the right to transfer unmodified vectors to others or the right to use the product for any commercial purpose (e.g. therapeutics, manufacturing, diagnostics or sale or fee-for-service use of animal models). Prospective users at for-profit institutions or those who wish to perform research on behalf of for-profit institutions or any other commercial purpose must contact Mirus Bio Corporation for a commercial license. If you require a commercial license to use this product and you decide not to take a license, please return the unopened product to Mirus Bio Corporation for a full refund.

In vivo hydrodynamic delivery of non-viral nucleic acids is covered by patents and patent applications of Mirus Bio Corporation, including U.S. Patent 6,627,616 and related filings worldwide. Purchase of these products does not provide a license to this delivery technology, which is required for all research and commercial uses by for-profit entities. To inquire about a license, please contact Mirus Bio Corporation.

This product is sold to the Buyer with a limited license to use this product for research only. This product, or parts from this product, may not be re-packaged or re-sold without written permission from Mirus Bio Corporation.

TransIT and MiraCLEAN are registered trademarks of Mirus Bio Corporation.

© 2005, Mirus Bio Corporation. All rights reserved.